Rhumbline Advisers Has $1.92 Million Holdings in InMode Ltd. (NASDAQ:INMD)

Rhumbline Advisers lessened its holdings in InMode Ltd. (NASDAQ:INMD) by 3.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 115,028 shares of the healthcare company’s stock after selling 4,634 shares during the quarter. Rhumbline Advisers owned 0.14% of InMode worth $1,921,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in INMD. Harvey Capital Management Inc. lifted its position in InMode by 1.4% during the 4th quarter. Harvey Capital Management Inc. now owns 51,490 shares of the healthcare company’s stock worth $860,000 after buying an additional 700 shares in the last quarter. Meritage Portfolio Management increased its position in shares of InMode by 12.3% in the fourth quarter. Meritage Portfolio Management now owns 16,575 shares of the healthcare company’s stock valued at $277,000 after acquiring an additional 1,810 shares during the last quarter. DGS Capital Management LLC raised its holdings in InMode by 129.7% during the fourth quarter. DGS Capital Management LLC now owns 24,704 shares of the healthcare company’s stock worth $413,000 after acquiring an additional 13,948 shares in the last quarter. CWA Asset Management Group LLC acquired a new position in InMode during the fourth quarter valued at approximately $367,000. Finally, Franklin Resources Inc. boosted its position in InMode by 4.6% during the third quarter. Franklin Resources Inc. now owns 17,559 shares of the healthcare company’s stock valued at $292,000 after purchasing an additional 768 shares during the last quarter. Institutional investors and hedge funds own 68.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on INMD. Needham & Company LLC reiterated a “hold” rating on shares of InMode in a research note on Tuesday, February 4th. Barclays boosted their target price on shares of InMode from $26.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, February 5th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $22.25.

InMode Stock Up 0.9 %

NASDAQ:INMD opened at $18.89 on Tuesday. InMode Ltd. has a 12-month low of $14.87 and a 12-month high of $23.46. The stock’s 50 day moving average price is $17.59 and its two-hundred day moving average price is $17.43. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of 8.04 and a beta of 2.13.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.